The phenomenon was particularly intense in “triple-negative” breast tumors [55,56,57], consequently HspB5 is now considered as a biomarker in the diagnosis of breast cancers, especially in those with advanced grade [57,58]. This evidence concerns the gene CRYAB and breast carcinoma.